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The introduction of radiation therapy (RT) with concurrent temozolomide (TMZ) chemotherapy 
resulted in a major shift in the treatment of adult patients with glioblastoma. The EORTC-NCIC trial 
(the Stupp trial) confirmed significant improvement in overall survival and set the standard of care 
as 60 Gy in 30 fractions of RT with TMZ daily, followed by 6 months of adjuvant TMZ (1). Further, 
for the first time, the field of neuro-oncology realized patients with glioblastoma who were achieving 
longer-term survival, with nearly 40% alive at 2 years, and nearly 10% alive at 5 years (2).
Unfortunately, these successes have not translated into gains for elderly patients with glioblas-
toma. The EORTC-NCIC data offer little direction regarding best practice for the treatment of elderly 
patients with glioblastoma, as only a minority of patients enrolled in the Stupp trial were older than 
age 65, and patients older than 70 were excluded. Further, exploratory analyses of the EORTC-
NCIC data suggest that increasing age attenuates the benefit of addition of TMZ to glioblastoma 
therapy, with less survival benefit among patients 65–70 years of age [hazard ratio for death, 0.78; 
95% confidence interval (CI), 0.50–1.24; P = 0.29] than among younger patients (3). Meanwhile, the 
incidence of glioblastoma in the elderly population has been rising (4), bringing with it a growing 
need to delineate a standard of care for elderly patients.
Anecdotal evidence and previous trial data offered good reason for these patients to have been 
excluded from the Stupp trial. Many elderly individuals simply cannot tolerate standard RT, let alone 
combined therapy (5). As it is, the significant biological and functional heterogeneity of this cohort 
of glioblastoma patients [“not every eighty year old is an eighty year old” (6)] and the many iterations 
of therapy available their treatment, has resulted in a diverse approach to the care of glioblastoma in 
elderly patients, as observed in an analysis captured in the SEER registry (7). Defining the standard 
of care in elderly patients with glioblastoma has been of major interest, but has remained to now an 
unanswered question.
That treating elderly patients with glioblastoma is appropriate was in itself a question not so long 
ago. The answer to this question was elucidated by Keime-Guibert and colleagues, who in 2007 
published a randomized controlled trial of 85 patients with a Karnofsky performance score of 70 
or greater comparing supportive treatment alone to RT (50.4 Gy in 28 fractions) plus supportive 
care for glioblastoma patients over 70 years of age (the ANOCEF trial) (8). The study was stopped 
at the first interim analysis due to the finding that survival in the RT plus supportive care group was 
superior to supportive care alone. Median overall survival for patients who received support care 
plus radiotherapy was 6.7 months, compared to 3.9 months in patients treated with supportive care 
alone. Importantly, the study found that the survival benefit offered by RT to elderly patients did not 
come at the cost of health-related quality of life.
The options for therapy in this population expanded with the 2012 study from the Nordic Brain 
Tumor Clinical Study Group (the Nordic trial) (9). Nordic randomized 342 patients over 65 years 
of age with a good performance status (ECOG 0-2) to three single-modality treatment arms: 
(1) standard-dose TMZ; (2) standard RT (60 Gy in 30 fractions); or (3) hypofractionated RT (34 Gy in 
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10 fractions). 291 patients underwent treatment with a primary 
endpoint of overall survival and secondary endpoints of health-
related quality of life and safety. Patients deemed eligible for 
chemoradiation were excluded. The median overall survival was 
significantly longer in patients treated with TMZ (8.3 months) 
or hypofractionated RT (7.5  months) compared to those who 
received standard RT (6.0  months). O6-methylguanine–DNA 
methyltransferase (MGMT) promoter methylation was associ-
ated with significantly higher survival rates in patients treated 
with TMZ (9.7  months vs. 6.8  months), but had no effect on 
survival in patients treated with RT. No difference in survival was 
found in patients with an unmethylated MGMT promoter treated 
with RT or single-agent TMZ (7.0 vs. 6.8  months). Patients in 
the TMZ group generally reported better quality of life than did 
patients in the RT groups, but the ratings for global health status 
were equal.
Perry and colleagues from the CCTG/EORTC Trial Investigators 
Intergroup have now brought us one step closer to an answer. In 
CCTG CE.6/EORTC 26062-22061/TROG patients 65  years of 
age or older with newly diagnosed glioblastoma were randomly 
assigned to receive either RT alone (40  Gy in 15 fractions) or 
RT with concomitant and adjuvant TMZ (10). 562 patients were 
randomized. The median age was 73 years (range, 65–90). Patients 
deemed by their physicians to be suitable to receive conventional 
RT were excluded. Eligible patients had an ECOG performance 
status of 0, 1, or 2 and were receiving glucocorticoids at a stable or 
decreasing dose. Quality-of-life assessment was performed weekly 
during RT, then 1 week after the last day of RT, and then every 
3  months until disease progression, using the EORTC Quality-
of-Life Questionnaire-Core 30 (QLQ-C30) and the EORTC brain 
module (QLQ-BN20). Progressive disease was defined as objec-
tive radiographic progression. If brain imaging could not be per-
formed, symptomatic progression was used to define progression. 
The primary end point was overall survival, measured from the 
date of randomization until death or censoring at the last day that 
the patient was known to be alive. Progression-free survival was 
measured from the date of randomization until disease progres-
sion or death (if no progression was reported) or until the last 
evaluation date.
All 562 randomly assigned patients (281 in each group) 
were included in the intention-to-treat analysis. Among the 503 
samples examined centrally, glioblastoma was confirmed in 480 
(95.4%), high-grade glioma in 15 (3.0%), diffuse glioma lacking 
high-grade features in 5 (1.0%), and anaplastic oligodendroglioma 
in 3 (0.6%). Immunohistochemical staining for the IDH1 R132H 
mutation was positive in only 4 of the 481 specimens deemed 
suitable for analysis. Treatment adherence was high. The median 
duration of concomitant TMZ was 21  days, as planned. The 
median number of adjuvant cycles delivered was five. A similar 
percentage of patients in the two groups (197 of 493 patients, 
40.0%) received other anticancer therapies at disease progression. 
RT plus TMZ was associated with more adverse events than RT 
alone, with a higher rate of grade 3 or 4 events, but no difference 
between the two groups in terms of serious adverse events leading 
to death.
Baseline factors that correlated with overall survival included 
the extent of resection and MMSE score: patients with biopsy 
only had shorter survival than those with partial or complete 
resection. In Cox regression modeling with adjustment for base-
line factors, RT plus TMZ remained significantly better than RT 
alone with respect to overall survival, with an estimated hazard 
ratio of 0.67 (95% CI, 0.56–0.80; P < 0.001). The median overall 
survival was longer with RT plus TMZ than with RT alone (9.3 
vs. 7.6 months; hazard ratio for death, 0.67), as was the median 
progression-free survival (5.3 vs. 3.9  months; hazard ratio for 
disease progression or death, 0.50). Among 165 patients with 
methylated MGMT status, the median overall survival was 
13.5 months with RT plus TMZ and 7.7 months with RT alone 
(hazard ratio for death, 0.53). Interestingly, even patients with 
unmethylated MGMT status benefited from the addition of 
chemotherapy: among 189 patients with unmethylated MGMT 
status, the median overall survival was 10.0  months with RT 
plus TMZ and 7.9 months with RT alone (hazard ratio for death, 
0.75). Measures of quality of life showed no significant difference 
in the two trial groups. Further, exploratory analyses of overall 
survival at 12, 18, and 24 months suggested that the benefit of 
radiation and concurrent and adjuvant chemotherapy on OS 
is long standing. Unfortunately, combined therapy in elderly 
patients does not appear to garner long-term survivorship as it 
does in younger patients: the CE.6 trial cohort had no survivors 
beyond 3 years.
The CE.6 trial data, while methodologically sound, were 
at times scientifically difficult to make sense of. Patients with 
unmethylated MGMT derived a clinically meaningful if not 
statistically significant (P = 0.55) overall survival advantage 
from the addition of TMZ to RT. It is difficult to make sense 
of this outcome biologically, and difficult to reconcile it with 
findings from the Stupp trial, in which benefit from combined 
therapy was more pronouncedly realized in MGMT methyl-
ated patients. This discrepancy could be an artifact of the 
assay used in CE.6 to determine MGMT methylation status 
(real-time methylation-specific PCR), which risks “misclas-
sifying” patients with lower levels of MGMT methylation 
as unmethylated (11). Further, patients 65–70  years of age 
derived less benefit from the addition of TMZ than those 
71–75 years of age or 76 years of age or older. The CE.6 trial 
investigators adroitly suggest that this seeming discrepancy 
could be an indirect result of excluding younger elderly 
patients who were deemed to be eligible for standard (Stupp 
protocol) combined chemoradiation; in other words, the 
CE.6 trial may have been biased to include more robust older 
elderly patients, while accruing less medically fit younger 
elderly patients.
Many questions remain to be asked. For example, should 
medically eligible older patients receive standard (Stupp proto-
col) combined chemoradiation? And if so, what criteria should 
be used to determine which elderly patients are medically eligible 
for standard therapy? Conversely, are there elderly patients who 
should be treated with palliative RT alone, or some patients who 
would be better served by treatment with TMZ monotherapy? 
Finally, which assay should be used to determine MGMT meth-
ylation status? These questions will require future work. For now, 
Perry and colleagues should be congratulated for clarifying the 
path forward.
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